Jump to content



Recommended Posts

A good way to start the week......




Phylogica in collaboration with Pfizer

09:09, Monday, 20 December 2010

Sydney - Monday - December 20: (RWE Aust Business News) -Phylogica (ASX:PYC) has entered into a collaboration and licensing agreement with Pfizer to discover novel peptide-based vaccines. Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation. Under the agreement, Phylogica grants Pfizer certain rights,including an option to license any resulting Phylomers for further research, development and commercialisation of novel peptide-based vaccines derived from such Phylomers. Under the terms of the agreement, Phylogica will receive an upfront payment of USD500,000. In addition, Phylogica is eligible to receive a commerciallicence payment and is also eligible to receive preclinical, clinical and other milestone payments of up to USD134 million, as well as royalties on world wide sales. Phylogica has now entered into three alliances with global pharmaceutical companies within the last 12 months. ENDS

Copyright ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚© 2010 RWE Australian Business News. All rights reserved.
Link to comment
Share on other sites

  • Replies 1.5k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

Phylogica directors promised three deals by year end - we have three deals by year end. The latest deal is groundbreaking in that we have not heard of the deployment of phylomers in the vaccine space.


We have yet to hear of the Roche second phase of the very promising intracellular work.


The CD-40 ligand inflammation compound also needs a home.


Woolfe is promising three more new discovery partnerships, next year.


Given the prospects and the credibility gained in delivering what they promise ... I would expect that next year will be very exciting for shareholders.


While some will trade Phylogica, based on it's prospects and likely positive news flow - my view is that this is a strong buy and hold into the long term.

Link to comment
Share on other sites

my view is that this is a strong buy and hold into the long term


I think I remember you saying something like that about four years ago when they were trading above 30c with far far fewer shares and options on issue.


Meanwhile, as the deals keep on rolling on the only thing to debate is which is the biggest peanut.



Pfizer/Phylogica: Australian peptide drug discovery specialist Phylogica has struck its third licensing deal in the past year, agreeing to allow Pfizer to discover peptide-based vaccines using its proprietary platform. Pfizer will pay just $500,000 upfront for the license, but downstream payments, options and royalties of undisclosed size could potentially drive the deal's value as high as $134 million. Founded in 2001, the Perth-based company has also signed separate licensing agreements with Roche and AstraZeneca's Medimmune subsidiary. The Roche deal covers a mechanism allowing large molecules to attack disease targets inside of cells, while the MedImmune deal addresses antimicrobial peptides that attack the Gram-negative bacterium Pseudomonas aeruginosa. The latter deal, revealed in August 2010, includes a small upfront commitment of just $750,000 plus a 12-month commitment that will double that amount.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâہ¡ÃƒÆ’‚ÂÂPB
Link to comment
Share on other sites

  • 3 weeks later...

It is still possible PYC will do a MorphoSys by making a placement with a pharma for some astronomical sum but it is really looking like multiple licencing deals and then takeover by preferred suitor.


Considering Merck have tied up with Auckland University and AgResearch according to the bar tender in the on-campus watering hole Shadows, it is not out of the realm to think AU, AgRe. and MRK have their foot on the throat of PYC. Especially when you consider who their ex-chairman is.


MRK have said they wish to partner before takeover. So the likelihood of a MorphoSys deal soon is high before it is low IMHO.


Strange there is no trading today after so much volume the last couple of weeks. Is it in a trading halt? News pending?

Link to comment
Share on other sites

" Is it in a trading halt? News pending?"




Phylogica alliance with XL-protein

13:48, Thursday, 13 January 2011

Sydney - Thursday - January 13: (RWE Aust Business News) -Phylogica (ASX:PYC) has an alliance with XL-protein GmbH, a German-based biotech company that specialises in extending the circulation half-life of biopharmaceuticals. Through this alliance, Phylogica gains access to a unique modification technology that strengthens the Phylomer drug discovery platform. Phylogica and XL-protein will initially collaborate on a pilot study to validate the technology in combination with one of Phylogica's Phylomer peptides targeting CD40 ligand from its in-house anti-inflammatory program. Under the terms of the agreement, Phylogica has an option to obtain an exclusive license to the PASylation technology for peptide-based products in relation to CD40 ligand and has rights of negotiation for a licence to the technology for Phylomers that bind other targets. It is anticipated that the plasma half-life of PASylated Phylomers will be significantly extended, making them more suitable for less frequent administration and at lower dose. Long acting Phylomers would be ideal for treating chronicindications, such as rheumatoid arthritis, coronary artery disease and inflammatory bowel disease, in which CD40 ligand has been implicated as a potential target. ENDS

Copyright ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚© 2011 RWE Australian Business News. All rights reserved.
Link to comment
Share on other sites

  • 2 weeks later...

The Company Announcements Platform


Sydney NSW 2000

January 24, 2011

Press Release Phylogica Ltd (ASX PYC)

Phylogica Receives Prestigious Frost & Sullivan Innovation Award

PERTH, AUSTRALIA, January 24, 2011 - Phylogica Ltd (ASX: PYC, XETRA: PH7), a

leading Australian drug discovery company, announced today that it has received the

2011 Asia Pacific Frost & Sullivan New Product Innovation Award for Peptide

Screening Technologies for its PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® platform. This prestigious award

underscores PhylogicaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s leadership in realising the untapped potential of natureÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s vast

biodiversity to discover novel peptide-based drugs.

Frost & Sullivan is a global growth consulting company and it presents these awards to

companies demonstrating measured excellence and technological advancement within

their field across a variety of regional and global markets.

In bestowing this award to Phylogica, Frost & Sullivan highlighted the CompanyÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s

expertise in peptide screening and also the uniqueness of its Phylomer peptide

libraries. These libraries compromise billions of natural peptides derived from an

evolutionary diverse range of microbial genomes. Phylogica has integrated its

Phylomer libraries with a suite of high-throughput screening technologies to create an

efficient drug discovery platform based on the worldÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s most structurally diverse peptide


PhylogicaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s Chief Executive Officer, Dr Paul Watt, said: "We are proud to have

received this award from Frost & Sullivan, which is further acknowledgment that our

Phylomer platform is at the forefront of peptide drug discovery. Phylogica is gaining

increasing recognition within the pharmaceutical industry as a valued collaborative

partner with world-class technology. There is growing interest in peptide therapeutics

for the treatment of a wide range of diseases and we are well positioned to take

advantage of these market dynamics to accelerate our growth.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ



Link to comment
Share on other sites

Press Release Phylogica Ltd (ASX PYC)

Phylogica Named as One of Bioshares 'Top 10 Picks' for 2011

PERTH, AUSTRALIA, January 25, 2011 - Phylogica Ltd (ASX: PYC, XETRA: PH7), a

leading Australian drug discovery company, announced today that it has been named

as one of the annual Bioshares 'Tops 10 Picks' of investment opportunities.

Bioshares is a leading Australian industry journal that provides independent

investment analysis on the ASX biotechnology sector. The top ten stocks are chosen

from more than 100 public companies on the basis that the shares are expected to

outperform the market and post significant returns over a 12-month period. The full

Bioshares article on Phylogica is available to download here: from the company's




Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...